Provided by Tiger Trade Technology Pte. Ltd.

Tenaya Therapeutics Inc

0.6973
+0.00680.98%
Post-market: 0.71000.0127+1.82%19:54 EDT
Volume:1.15M
Turnover:814.54K
Market Cap:156.20M
PE:-1.31
High:0.7200
Open:0.6929
Low:0.6926
Close:0.6905
52wk High:2.35
52wk Low:0.5316
Shares:224.00M
Float Shares:223.00M
Volume Ratio:0.50
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5333
EPS(LYR):-0.5922
ROE:-121.86%
ROA:-47.91%
PB:2.25
PE(LYR):-1.18

Loading ...

Tenaya Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 16

Tenaya’s TN-401: Differentiated PKP2 Gene Therapy Opportunity Underpins Favorable Risk–Reward and Buy Rating

TIPRANKS
·
Apr 14

Tenaya Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 12

Tenaya Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 12

Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027

Reuters
·
Mar 12

Tenaya Therapeutics reports Q4 EPS (12c), consensus (12c)

TIPRANKS
·
Mar 12

Tenaya Therapeutics Q4 EPS $(0.12) Beats $(0.13) Estimate

Benzinga Earnings
·
Mar 12

BRIEF-Tenaya Therapeutics Q4 Net Income USD -20.175 Million Vs. IBES Estimate USD -22 Million

Reuters
·
Mar 12

Tenaya Therapeutics Q4 Operating Expenses USD 20.775 Million

THOMSON REUTERS
·
Mar 12

Press Release: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 12

Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy

GlobeNewswire
·
Mar 09

Tenaya Therapeutics: Alnylam Partnership Validates Cardiovascular Platform and Supports Long-Term Buy Thesis

TIPRANKS
·
Mar 06

Tenaya Therapeutics: Alnylam Collaboration De-Risks Platform and Expands Cardiovascular Upside, Supporting Buy Rating

TIPRANKS
·
Mar 06

Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments

Reuters
·
Mar 05

Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration

TIPRANKS
·
Mar 05

BRIEF-Tenaya Therapeutics Enters Into Research Collaboration With Alnylam Pharmaceuticals To Identify And Validate Novel Genetic Targets For Cardiovascular Disease Therapeutics

Reuters
·
Mar 05

Tenaya Therapeutics Inc - Co to Validate up to 15 Gene Targets Under Agreement

THOMSON REUTERS
·
Mar 05

Tenaya Therapeutics Enters Into Research Collaboration With Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

THOMSON REUTERS
·
Mar 05

Tenaya Therapeutics Inc - to Receive up to $10 Mln Upfront and up to $1.13 Bln in Milestone Payments

THOMSON REUTERS
·
Mar 05

Tenaya Therapeutics to Join Leerink Partners Global Healthcare Conference in Miami

Reuters
·
Mar 03